Evidence map›Paper›PMID 41869725›Full record

ArticleJCI insight2026

Extracellular vesicle miR-93-5p cargo regulates glomerular endothelial cell damage in Alport syndrome.

Charmi Dedhia, Valentina Villani, Xiaogang Hou, Paolo Neviani, Geremy Clair, Mohammadreza Kasravi, Cristina Grange, Paolo Cravedi, Paola Aguiari, Velia Alcala and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Charmi DedhiaThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Valentina VillaniThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Xiaogang HouThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Paolo NevianiExtracellular Vesicle Core, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Geremy ClairBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Mohammadreza KasraviThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Cristina GrangeDepartment of Medical Sciences, University of Turin, Turin, Italy.
Paolo CravediDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Paola AguiariThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Velia AlcalaThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Giuseppe OrlandoSection of Transplantation, Department of Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
Xue-Ying SongApplied Genomics, Computation, and Translational Core, Cedars-Sinai Medical Center Los Angeles, California, USA.
Jonathan E ZuckermanDepartment of Pathology and Lab Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Roger E De FilippoThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Stefano Da SaccoThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Sargis SedrakyanThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.
Benedetta BussolatiDepartment of Medical Sciences, University of Turin, Turin, Italy.
Laura PerinThe GOFARR Laboratory, The Saban Research Institute, Division of Urology, and.

Funding

Mechanisms involved in podocyte damage in Alport SyndromeR01DK133459 · NIDDK · CHILDREN'S HOSPITAL OF LOS ANGELES · PI Stefano Da Sacco, Laura Perin · 2022 to 2026
$3.2M
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.R01DK121037 · NIDDK · CHILDREN'S HOSPITAL OF LOS ANGELES · PI PERIN, LAURA · 2020 to 2023
$2.2M
NIDDK NIH HHS R01 DK121037NIDDK NIH HHS R01 DK133459
6 · The paper itself

Abstract

Modulation of miRNA expression in glomerular cells is associated with renal disease. Here, we investigated the role of miR-93-5p in mitigating glomerular damage in Alport syndrome and whether the disease-modifying activity of extracellular vesicles from human amniotic fluid stem cells (hAFSC-EVs) is mediated by their miR-93-5p cargo. We identified downregulation of miR-93-5p specifically in glomerular endothelial cells in Alport syndrome along disease progression. Silencing of miR-93-5p in hAFSC-EVs changed the transcriptomic and proteomic profile, regulating EV disease-modifying activity. Compared with naive hAFSC-EVs, silenced hAFSC-EVs did not rescue glomerular endothelial function in vitro and did not restore kidney function in vivo. We established that hAFSC-EVs regulate VEGFR1 and VEGFR2 signaling by miR-93-5p cargo transfer, highlighting that miR-93-5p can restore glomerular endothelial cell biology. Spatial transcriptomics analysis of hAFSC-EV-injected kidneys showed that these EVs can reverse pathways altered during disease progression by stimulating proregenerative processes, specifically in the glomerulus, by regulating miR-93-5p targets. Alteration of glomerular endothelial cell transcriptomics and miR-93-5p targets was also confirmed in biopsies of patients with Alport syndrome using spatial molecular imaging. We demonstrated the critical role of miR-93-5p in glomerular endothelial cells and the capability of hAFSC-EVs to regulate miR-93-5p and its targets in Alport syndrome.

Indexed as

Endothelial CellsExtracellular VesiclesKidney GlomerulusMicroRNAsNephritis, HereditaryAmniotic FluidAnimalsFemaleHumansMaleMiceSignal TransductionStem CellsVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2KDR protein, humanMicroRNAsMIRN93 microRNA, humanVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Cell biologyChronic kidney diseaseNephrology

Identifiers

PMID41869725
PMCPMC13043101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.